Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational, Prospective, Open Labelled, Non-controlled, Non-interventional Post-authorisation Study of Turoctocog Alfa Pegol (N8-GP) During Long-term Routine Prophylaxis and Treatment of Bleeding Episodes in Patients With Haemophilia A

NCT04574076 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT04574076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04574076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational, Prospective, Open Labelled, Non-controlled, Non-interventional Post-authorisation Study of Turoctocog Alfa Pegol (N8-GP) During Long-term Routine Prophylaxis and Treatment of Bleeding Episodes in Patients With Haemophilia A
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Enrolling by invitation
Start date
October 23, 2020
Completion date
June 3, 2027
Enrollment
60 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

haemophilia a